Skip to Main Content

Paper Details

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
JCI Insight
40
2019
CIP2A, EGFR, EGFRL858R, LUAD, MAPK, PI3K, PP2A, TKI, TKI-sensitive cell lines, advanced lung adenocarcinoma, afatinib, lung adenocarcinoma, mouse, patients, protein phosphatase 2A, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Rita TohmeCleveland Clinic
Rita TohmeCase Comprehensive Cancer Center, Case Western Reserve University
Sudeh IzadmehrTisch Cancer Institute.
Sai GandheCase Comprehensive Cancer Center, Case Western Reserve University
Giancarlo TabaroCase Comprehensive Cancer Center, Case Western Reserve University
Sanjay VallabhaneniCase Comprehensive Cancer Center, Case Western Reserve University
Anju ThomasCase Comprehensive Cancer Center, Case Western Reserve University
Neal VasireddiCase Comprehensive Cancer Center, Case Western Reserve University
Neil S Dhawan
Avi Ma'ayanDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Avi Ma'ayanDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Neelesh SharmaUniversity Hospitals Seidman Cancer Center, Case Western Reserve University
Matthew D Galsky
Michael OhlmeyerIcahn School of Medicine at Mount Sinai
Michael OhlmeyerIcahn School of Medicine at Mount Sinai
Jaya SangodkarUniversity of Michigan ann arbor
Jaya SangodkarUniversity of Michigan ann arbor
Goutham NarlaUniversity of Michigan ann arbor
Goutham NarlaUniversity of Michigan ann arbor
  • 1 - 19

Datasets

Release 1.2